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ABSTRACT Studies in Shaker, a voltage-dependent potassium channel, suggest a coupling between activation and inactiva-
tion. This coupling is controversial in hERG, a fast-inactivating voltage-dependent potassium channel. To address this question,
we transferred to hERG the S3-S4 linker of the voltage-independent channel, rolf, to selectively disrupt the activation process.
This chimera shows an intact voltage-dependent inactivation process consistent with a weak coupling, if any, between both
processes. Kinetic models suggest that the chimera presents only an open and an inactivated states, with identical transition
rates as in hERG. The lower sensitivity of the chimera to BeKm-1, a hERG preferential closed-state inhibitor, also suggests
that the chimera presents mainly open and inactivated conformations. This chimera allows determining the mechanism of action
of hERG blockers, as exempliﬁed by the test on ketoconazole.INTRODUCTION
The human ether-a`-go-go-related gene KCNH2 encodes the
a-subunit of the ion channel (hERG) underlying the cardiac
delayed rectifier Kþ current, IKr (1). hERG is a member of
the voltage-gated Kþ (Kv) channel family. Similar to other
Kv, its a-subunit contains six putative transmembrane
segments (S1-S6), a P-loop, several charged residues in
segments S2 and S3, and positively charged residues in S4
that are conserved among voltage-gated channels (2). The
presence of a cyclic nucleotide binding site in its C-terminal
end suggests that it derives from a common evolutionary
ancestor with the superfamily of cyclic nucleotide-gated
channels (3). In the human heart, IKr plays a prominent role
in the phase 3 of the action potential and not during the phase
1 or 2 when fast inactivation limits the contribution of IKr to
repolarization. This profile is due to the unusual kinetics of
hERG gating, with slow activation and fast inactivation (1).
Despite its unusual kinetic properties and intrinsic voltage
dependence, hERG inactivation is termed C-type because of
its sensitivity to TEAþ (4).
Hoshi et al. (5) studied the properties of the C-type inacti-
vation process in Shaker, another voltage-dependent Kþ
channel. They have shown that the time constant of C-type
inactivation is voltage independent between 25 and
þ50 mV. They concluded that if this voltage independence
is maintained at lower voltages, C-type inactivation is
not intrinsically voltage-dependent and must be partially
coupled to activation. More recently, Panyi and Deutsch
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0006-3495/09/09/1323/12 $2.00(6) have shown in Shaker that the rate of activation depends
on the state of the inactivation gate, suggesting that activa-
tion and inactivation are coupled. For hERG, the coupling
of activation and inactivation processes remains controver-
sial (7,8). One way to address this question would be to
use a mutant of hERG stabilized in the activated configura-
tion and to study the impact on the inactivation process.
The mutation D540K in the S4-S5 linker of the hERG
channel causes a stabilization in the open state at negative
voltages (9). The drastic changes in its activation properties
are accompanied with a moderate change in its inactivation
properties, suggesting a weak coupling between activation
and inactivation processes. The D540K mutation may not,
however, be the most relevant to test this coupling because
the S4-S5 linker interacts with the pore domain (10).
Because hERG inactivation results from a modification of
the pore conformation, the observed effect of the mutation
on inactivation may be direct, and not through activation.
Consistent with this, the D540K channel shows a decreased
sensitivity to MK-499, a blocker of hERG, known to interact
with the pore lining S6 domain (11). Thus, stabilizing hERG
in the open configuration without directly modifying the
pore structure may require modifying a region further from
the pore. In an attempt to prevent a direct effect on inactiva-
tion and to specifically target the S4 functionality, by suppos-
edly constraining its movement, we mutated the S3-S4
region that is far from the pore domain, based on the Kv1.2
structure (12).
In 1997, a study by Tang and Papazian (13) showed that
the voltage independence of the cyclic nucleotide-gated
channel rolf (‘‘rat olfactory channel’’) can be transferred to
Drosophila eag, the ether-a`-go-go channel, by replacing
the eag S3-S4 loop by the corresponding rolf S3-S4 loop.
When transferred into eag, the S3-S4 loop of rolf increases
the stability of the open conformation and shifts the voltage
doi: 10.1016/j.bpj.2009.05.060
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We hypothesized that replacing the hERG S3-S4 loop by
the rolf S3-S4 loop would stabilize the channel in the
same manner as in the eag chimera channel. We made
such a chimera and the channel obtained barely deactivates,
consistent with the hypothesis. The modification of the acti-
vation process does not modify the voltage dependence and
the kinetics of inactivation. These results suggest a weak
coupling, if any, between activation and inactivation in
hERG channels. In the physiological range of the cardiac
action potential (from 90 to þ 30 mV), the chimeric
channel seems to present only two conformations: open and
inactivated.
This chimera may be useful to accurately characterize the
state-dependent block of hERG inhibitors and discriminate
possible affinity for the closed state. The mechanism of
hERG inhibition by ketoconazole remains controversial
(14–16). We took the opportunity of this chimeric channel
to study the inhibition by ketoconazole. This drug has been
described successively as a preferential closed-state blocker
(14,16) and as a preferential open or inactivated-state blocker
(15). The use of the chimera shows that ketoconazole prefer-
entially inhibits open and inactivated hERG channels.
METHODS
Molecular biology
Thechimerawas constructed by three-stepPCR.TheDNAsequence encoding
the hERG S3-S4 linker (NH2-SGSEELIGLL-COOH)was replaced by that of
rolf (rat olfactory potassium channel) (NH2-AVGIHSPEV-COOH) using the
following primers (50-GCAGTAGGAATTCATTCACCAGAAGTAAAGA
CTGCGCGGCTGCTGCGGCT GGTGCGC-30; 50-GGGAGATCTTCTCT
GAGTTGGTGTTGG-30). The PCR product was purified by agarose gel elec-
trophoresis (DNA extraction kit; Qiagen, Courtaboeuf, France), sequenced
and then cloned into pIRES-CD8.
Cell culture and transfection
African green monkey kidney fibroblast-like cell line (COS-7) was obtained
from the American Type Culture Collection (Rockville, MD) and cultured as
described previously (17). Cells were transfected with DNA (2 mg/mL of
culture medium) complexed to JetPEI (Polyplus-Tranfection, Strasbourg,
France) according to the manufacturer’s instructions. Eight hours later, the
cellswere isolated, diluted, and seeded in 35-mmpetri dishes. In hERGexper-
iments, COS-7 cellswere cotransfectedwith 0.8mg of hERG (pSI hERG) (18)
and 1.2 mg of pEGFP (Clontech, Palo Alto, CA) coding for the green fluores-
cence protein. In chimera experiments, COS-7 cells were transfected with
2 mg of pIRES-chimera-CD8. Dynabeads CD8 (Invitrogen Dynal AS,
Norway) were used to identify the cells expressing the chimera. hERG and
the chimeric channel densities at the sarcolemma were probably equivalent
because the current densities were not significantly different (unpaired
t-test; hERG: 225 7 pA/pF, n ¼ 8; chimera: 195 6 pA/pF, n ¼ 8).
Patch-clamp recordings
Ion currents from hERG- and chimera-transfected COS-7 cells were recorded
using the whole-cell configuration of the patch-clamp technique. Cells were
placed on the stage of an inverted microscope and continuously superfused
with the standard extracellular medium. Patch pipettes with a tip resistance
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patch 200A;Axon Instruments, FosterCity,CA). Stimulation, data recording,
and analysis were carried out through an A/D converter (Tecmar TM100
Labmaster; Scientific Solutions, Solon, OH) and using Acquis1 software
(Bio-Logic, Claix, France). A microperfusion system allowed local applica-
tion and rapid change of the different experimental solutions. The cell capac-
itance was determined by analyzing the capacitive current recorded during
a step to 70 mV applied for 50 ms from a holding potential of 60 mV.
Current values were normalized using cell capacitance. For inactivation and
recovery from inactivation studies, capacitance and series resistance were
electronically compensated.
To study the voltage dependence of hERG and the chimera activation,
membrane potential was stepped, in 10-mV decrements, from a holding
potential of 80 mV to various voltages between þ50 mV and 130 mV,
and then back to 60 mV, every 3500 ms (Fig. 1).
The voltage dependence of hERG activation was determined by fitting the
normalized tail current (Itail) versus prepulse voltage (Vpp) relationship with
a Boltzmann equation:
Itail=Itail max ¼ 1=ð1 þ expð  ðVpp V0:5Þ=kÞ; (1)
where Itailmax is the maximum tail current, V0.5 is the half-activation poten-
tial, and k, the slope factor. The time constants of deactivation (t1 and t2)
were determined by a two-exponential fit to the tail current using the
following equation:
I=Ip ¼ A1  expð  t=t1Þ þ A2  expð  t=t2Þ þ Iss;
(2)
where I represents the current amplitude at time t, Ip is the peak tail current,
t1 and t2 are the time constants for the fast and slow components of the
deactivating current, A1 and A2 are the relative amplitude of each compo-
nent, and Iss the relative residual current component.
hERG inactivation was studied with two different three-pulse protocols
(Fig. 2). In the first protocol (Fig. 2 A), hERG-expressing cells were repolar-
ized (second pulse) for 5 ms to allow recovery from inactivation, with
minimum deactivation. Voltage dependence of hERG or chimera inactiva-
tion was observed during the third voltage pulse. This protocol allowed
measuring the inactivation rate constant at various membrane potentials,
and to establish the inactivation curve, but only at potentials at which deac-
tivation is slow (>60 mV). The second protocol (see Fig. 2 C and Zou
et al. (8)) enables compensation for the fraction of deactivation at potentials
lower than 60 mV during the second step. During this step, recovery from
inactivation is faster and distinguishable from deactivation. Deactivation is
thus evaluated from the decreasing part of the current during this step, and
compensated. The voltage dependence of inactivation was determined by
fitting the relative inactivating currents at þ60 mV versus voltage with
a Boltzmann equation similar to Eq. 1.
Recovery from inactivation was evaluated using a two-pulse protocol
(Fig. 3).
The time constants of inactivation (tinact) and recovery from inactivation
(trec inact) were measured using a single-exponential fit to the tail current
using the following equation:
I ¼ A  expð  t=tÞ þ C; (3)
where I represents current amplitude at time t, t is the time constant of inac-
tivation or recovery from inactivation, C þ A represents the initial current
amplitude, and C describes the current amplitude after inactivation/recovery
from inactivation. Kinetics of recovery from inactivation were fitted on the
first 2–10 ms.
All experiments were carried out at 35C. Patch-clamp data are presented
as mean5 SE. Statistical significance of the observed effects was assessed
by means of unpaired or paired Student’s t-tests, one-way, or two-way anal-
ysis of variance with a Tukey test when needed. A value of p < 0.05 was
considered significant.
Properties of a Two-State hERG Mutant 1325FIGURE 1 Voltage dependence of hERG and the chimera activation. Representative whole-cell current recordings from COS-7 cells expressing (A)
wild-type hERG or (B) chimeric channels. (Inset) Voltage stimulation, every 3.5 s. (C) Current density measured at the end of the prepulse versus voltage
in cells expressing hERG (n ¼ 8) or chimeric (n ¼ 8) channels. (D) Relative tail current measured at 60 mV versus prepulse potential in cells expressing
hERG (n ¼ 8) or chimeric (n ¼ 8) channels. hERG steady-state activation was determined by fitting hERG data with a Boltzmann function (solid line).E-4031 dose-response curves were fitted using the modified Hill equation:
y ¼ 1 d þ d=1 þ ðx=IC50Þh

; (4)
where d is the fraction of current that is sensitive to E-4031, x is the drug
concentration, h the Hill coefficient, IC50 is the concentration at which the
half-maximal peak tail currents were obtained, and y is the fraction of current
remaining at concentration x of E-4031.
Solutions and drugs
The standard extracellular medium contained 145 mM NaCl, 4 mM KCl,
1 mMMgCl2, 1 mM CaCl2, 5 mM HEPES, and 5 mM glucose, pH adjusted
to 7.4 with NaOH. The intracellular medium contained 74.5 mM KCl,
70.5 mM K-aspartate, 5 mM HEPES, 2 mM EGTA, 2 mM K2ATP, and
0.3 mM MgCl2 pH 7.2 with KOH. All products are from Sigma-Aldrich
(St. Quentin Fallavier, France).
Ketoconazole (Sigma-AldrichChimie)was dissolved inDMSO to produce
a 10-mM stock solution stored at 20C and further diluted in extracellular
medium. Recombinant BeKm-1 toxin (rBeKm-1, Alomone, Israel) was dis-
solved in 10 mM Tris-HCl, 1 mM EDTA, pH 7.6 to produce a 25 mM stock
solution stored at 20C. Final experimental concentration was reached by
dilution in the locally perfused extracellular medium: 145 mM NaCl, 4 mM
KCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM HEPES, 5 mM glucose, and
30 mMmannitol, pH adjusted to 7.4 with NaOH. In 100 mM [Kþ]o solution,
96 mM NaCl was replaced by KCl.
E-4031 (Sigma-Aldrich Chimie) was dissolved in water to produce a
10-mM stock solution stored at 20C and further diluted in the locally
perfused extracellular medium for final experimental concentration.Kinetic models
The Markov state model for hERG (Fig. 4 B) was adapted from Clancy and
Rudy (19). The single open state was named O, the inactivated state I, and
closed states C1–C3. Currents were computed according to I ¼ N  g 
PO  (Vm  Vi), where I is the current, N  g represents the maximal
conductance of the membrane, and PO, the open probability. The parameter
N  g and the transition constants were optimized to simulate a representa-
tive recording. The inversion potential Vi was set to 80 mV. Optimization
was carried out with ModelMaker v4.0 (AP Benson,Wallingford, UK) using
the Marquardt method.
RESULTS
The rolf-hERG S3-S4 chimera is activated
at negative potentials
On transfection with hERG cDNA, COS-7 cells expressed
a large Kþ current with biophysical properties reminiscent
of the rapid component of the human cardiac delayed recti-
fier Kþ current (Fig. 1 A) (20). A slowly activating Kþ
current developed during depolarizations above 40 mV
with a maximum at a potential between þ10 and þ20 mV
in hERG-expressing cells (Fig. 1, A and C). With further
depolarization, the current amplitude decreased progres-
sively. This inward rectification of hERG is due to the
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1326 Choveau et al.FIGURE 2 hERG and the chimera have identical inactivation. (A andC) Representative inactivating current recordings of cells expressing hERG or chimeric
channels recorded with two protocols. (Inset) Three-pulse voltage protocol from holding potential 80 mV. Pulses duration: (A) first, 200 ms; second, 5 ms;
third, 200 ms, every 3 s; (C) first, 1000 ms; second, 5 ms; third, 50 ms, every 3 s. (B) Steady-state current (Issi measured 20 ms after the beginning of the pulse)
relative to the peak current (I0) recorded during the third pulse versus voltage in cells expressing hERG (n ¼ 8) or chimeric (n ¼ 7) channels. Steady-state
inactivation was determined by fitting the data (WT, solid circle; chimera, open circle; measured values that are not taken into account for the fit, gray circles)
with a Boltzmann function (solid line). (D) Peak current (I0) relative to maximal peak current (I0max) estimated by fitting current traces 1 ms after depolarization
and extrapolating to the beginning of the pulse (hERG, n ¼ 6; chimera, n ¼ 7). In the case of hERG current, I0 is corrected from the fraction of deactivation
measured during the second pulse. Steady-state inactivation was determined by fitting the data as in B.channel voltage-dependent inactivation (4,21). Analysis of
the tail current allowed us to characterize the half-maximum
activation voltage (V0.5) and slope factor (k), giving 4.95
2.3 mV and 8.95 0.6 mV (n ¼ 8), respectively (Fig. 1 D).
The hERG deactivation time course was obtained by fitting
the decay of tail current at 60 mV after full activation at
þ20 mV, by a two-exponential function. Time constants
were t1¼ 865 8 ms and t2¼ 4905 60 ms and the relative
amplitudes of the two components were A1 ¼ 0.56 5 0.06
and A2 ¼ 0.41 5 0.05, respectively. The relative residual
current component was Iss ¼ 0.03 5 0.01 (n ¼ 8).
The same study was undertaken on COS-7 cells expressing
the chimera. Unlike hERG channels, chimeric channels
produced an instantaneous Kþ current that was observed
during hyperpolarized potentials as well as depolarized
potentials (Fig. 1,B andC). The tail current displayed no deac-
tivation (Fig. 1 B) and the activation curve was voltage inde-
pendent (Fig. 1D). These results show clearly that the chimera
deactivation process is impaired, as it is in the case of the rolf-
eag chimera (13). However, an inward rectification was still
detected at more positive potentials with a maximum current
recorded at more negative potentials (~30 mV) than for
hERG current (between þ10 and þ20 mV) (Fig. 1 C).
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in the rolf-hERG S3-S4 chimera
Alteration of the activation process would not necessarily be
expected to affect inactivation. This is suggested by the pres-
ervation of an inward rectification in the chimera. To accu-
rately check for a potential modification of the inactivation
process, the voltage dependence of hERG and chimeric
channel inactivation were compared. Because it is difficult
to measure steady-state inactivation on hERG, because of
concomitant deactivation, two three-pulse protocols were
used (Fig. 2) (8,21,22). In the first protocol (Fig. 2 A),
hERG currents were activated by a 200-ms depolarizing
step to þ60 mV. The cell was then repolarized to 100 mV
for 5 ms to allow recovery from inactivation. Finally, a test
step was applied to different voltages to observe the current
inactivation kinetics. Fig. 2 shows hERG and the chimera
voltage dependence of inactivation. hERG currents recorded
during the test step were of large amplitude and rapidly inac-
tivated. For depolarizations, similar inactivating currents
were observed in COS-7 cells expressing the chimera
(Fig. 2 A). For hyperpolarizations, deactivation was detected
only in cells expressing hERG. The half-inactivation
Properties of a Two-State hERG Mutant 1327FIGURE 3 hERG and the chimera have identical inactivation and recovery from inactivation kinetics. Recovery from inactivation current traces of (A)
hERG and the (B) chimera. (Right) Time-expanded framed zone. (Inset) Voltage protocol, every 3 s. (C) Voltage dependence of the time constant of recovery
from inactivation for hERG (n¼ 6) and the chimera (n¼ 7) and voltage dependence of the inactivation time constant for hERG (n¼ 9) and the chimera (n¼ 9).Biophysical Journal 97(5) 1323–1334
1328 Choveau et al.FIGURE 4 Kinetic models of hERG and chimeric channels. (A, top) Representative whole-cell current recordings from COS-7 cells expressing hERG or
chimeric channels. (Inset) corresponding voltage protocols. (A, bottom) Simulated currents obtained with the hERG kinetic model (B) optimized to fit hERG
experimental currents. (Right) Simulated chimera currents were obtained with the chimera kinetic model (C) using the same transition rates as the hERG kinetic
model. No further optimization was used or needed.potential (V0.5) was evaluated from the remaining current
ratio (Issi/I0) after 20 ms of inactivation. For hERG, the fit
of the inactivation curve was done only with the data
measured at potentials>60 mV. For these potentials, deac-
tivation after 20 ms is small because the fast component time
constant of deactivation (t1), which represents 56% of the
deactivation process, is at least four times >20 ms. For the
chimera, the fit was also done only with the data measured
at potentials>60 mV, even though there is no deactivation
at lower potentials. However, it can be noticed that the data
measured at potentials lower than 60 mV (Fig. 2 B, gray
circles) are well fitted by the Boltzmann curve. V0.5 were
50 5 4 mV (n ¼ 8) and 47 5 5 mV (n ¼ 7; unpaired
t-test: not significant (NS)) for hERG and the chimera,
respectively. The corresponding k values were k¼ 295 1 mV
(n ¼ 8) and k ¼ 255 2 mV (n ¼ 7; unpaired t-test: NS) for
hERG and the chimera, respectively. To circumvent the bias
on inactivation measurement due to fast deactivation at
potentials lower than 60 mV, we used another three-pulse
protocol (Fig. 2, C and D). The second step at various poten-
tials (þ70 to 130 mV) allows the recovery from inactiva-
tion and the measurement of the fraction of deactivation (see
Methods). The initial current of the third step at þ60 mV is
proportional to the degree of inactivation at the end of the
second step (after correction of deactivation). The half-inac-Biophysical Journal 97(5) 1323–1334tivation potential (V0.5) was evaluated from the fit of the inac-
tivating current recordedduring the third step.V0.5were715
4mV (n¼ 6) and745 2mV (n¼ 7; unpaired t-test: NS) for
hERG and the chimera, respectively. The corresponding
k values were k ¼ 235 1 mV (n ¼ 6) and k ¼ 215 1 mV
(n¼ 7; unpaired t-test: NS) for hERGand the chimera currents
respectively. The two protocols used did not give similar V0.5
values. One reason is that the second protocol does not allow
measurements of steady-state inactivation at several poten-
tials: at10 to50mV, recovery from inactivation is slightly
too slow (Fig. 3 C) to reach a steady-state during the 5-ms
pulse. Nevertheless, our results show that the voltage depen-
dences of hERG and the chimera currents are similar, what-
ever protocol was used.
The first three-pulse protocol allowed us to compare the
time constant of inactivation for hERG and the chimera.
The averaged data are plotted in Fig. 3 C. The superimposi-
tion of the results shows that the voltage dependence of inac-
tivation kinetics is not modified in the chimera.
For hERG, the prepulse used for recovery from inactivation
can not exceed 5ms at100mV to haveminimal deactivation
whereas almost complete recovery from inactivation. The
absence of deactivation in the chimera allowed us to test
whether a longer prepulse (30 ms) impacts inactivation. The
value of V0.5 as well as the inactivation kinetics values were
Properties of a Two-State hERG Mutant 1329not modified and were identical to hERG values (see Fig. S1
in the Supporting Material). It can also be noticed that a weak
deactivation could be detected for the chimera current at very
negative potentials only (130mV; Fig. 2A and Fig. S1) indi-
cating a large shift of the activation curve toward very
negative potentials. The decrease in the tail current cannot
be a consequence of extracellular Kþ depletion due to large
Kþ influxes during the very negative prepulses (between
130 mV and 110 mV). Such extracellular Kþ depletion
would cause a shift of EK to a potential more negative than
80 mV, leading to an increase (and not a decrease) of the
tail current measured at 60 mV (Fig. 1 D).
Recovery from inactivation was studied using a two-pulse
protocol (Fig. 3) as in other works (21,23). This protocol
generated the rapid recovery of hERG current followed by
deactivation. As for inactivation, chimera and hERG recov-
eries from inactivation were similar (Fig. 3C). Again, a slight
deactivation of the chimera current could be detected at
130 mV only.
Several studies have shown that a high [Kþ]o strongly
slowed the inactivation kinetics in hERG channel (24,25). If
the inactivation process is not modified in the chimera,
increasing [Kþ]o should lead to the same effect as in WT
hERG. To check this hypothesis, we compared the effect of
100 mM [Kþ]o on the chimera and hERG inactivation. We
observed that increasing [Kþ]o from 4 to 100 mM strongly
slowed the inactivation kinetics of hERG, as previously
showed (n ¼ 8–9, two-way ANOVA, with a Tukey test,
p < 0.05). We observed similar effects on the chimera (n ¼
8–9, two-way ANOVA, with a Tukey test, p < 0.05). There
was no significant difference between the effects of [Kþ]o
on hERG and the chimera (n ¼ 8, two-way ANOVA, NS).
Several studies showed that a high [Kþ]o caused a shift
of the voltage-dependence of inactivation toward positive
potentials (8,24). We did not observe such a modification,
probably because of difference in the temperature and cellular
models used. The absence of effect was also observed in the
chimera (Fig. S2). Altogether, the results with 100 mM
[Kþ]o reinforce the idea that the chimera has an intact inacti-
vation process.
A kinetic model also supports an intact
inactivation process in the chimera
A more comprehensive way to compare hERG and the
chimeric channel inactivation are kinetic models. These
models allowed discriminating the effect of the S3-S4 linker
substitution on the inactivation and activation processes.
First, we optimized a kinetic model (Fig. 4) of the hERG
channel bearing three closed states, one open state, and
one inactivated state (19,22,26). A comparison between
measured and simulated currents (Fig. 4 A) and biophysical
parameters (Fig. S3) shows that this model accounts very
well for our experimental data. Transition rate values are
listed in Table 1. Noticing that the chimera currents can beroughly modeled with a two-state model, we checked
whether the transition between these two states might corre-
spond to the O-I transition of the hERG channel. Simulated
currents for the chimera were obtained with the chimera
model (Fig. 4 C) using the values of the transition rates (ai
and bi) derived from hERG model optimization. Measured
chimera currents and biophysical parameters were rather
well fitted by this prediction in the range of physiological
voltages, without further optimization (Fig. 4 A and Fig. S3).
This result reinforces the proposition of an intact inactivation
transition in the chimera, identical to that of the hERG
channel. To get an accurate determination of the transition
rates, we imposed as many constraints as possible by fitting
both the current recordings and the biophysical parameters.
However, it is inherent to a 15 free parameters optimization
that its solution is not unambiguous and cannot be distin-
guished easily from others that also give good fits of the
data. In the framework of the model of hERG transitions
that we used, it is noteworthy that the O-I transition rates
strongly determine the inactivation kinetics. The very good
fits of the inactivation and recovery from inactivation time
constants (Fig. S3) suggest that the determination ofO-I tran-
sition rates for hERG is reasonably accurate. The conclusion
regarding the conservation of theO-I transition rates between
hERG and the chimera should thus be robust despite uncer-
tainties coming from the optimization process.
Chimera inhibition by BeKm-1
is voltage-independent
The chimera kinetic model suggests that the chimera exists in
two conformations: open and inactivated. To test this hypoth-
esis, we studied BeKm-1 effects on the chimera and hERG
(Fig. 5). BeKm-1 binds to the external face of the hERG
channel and has been shown to exhibit preferential closed-
state blockade (27,28). A 12-s ascending voltage ramp was
applied in baseline conditions. In these conditions, hERG
current developed from 40 mV with maximum amplitude
at ~0 mV. With further depolarization, the current amplitude
decreased progressively (Fig. 5 A). The chimera was already
activated at the beginning of the ramp (80 mV), generating
a maximum current at ~40 mV, which declined due to
TABLE 1 hERG and the chimera transition rates (ms1)
hERG transition rates (ms1)
a 2.987  103 exp(9.377  102  Vm)
b 1.872  102
ain 5.755  101
bin 1.056  101
aa 1.55  102 exp(2.464  102  Vm)
bb 1.7  103 exp(2.37  102  Vm)
a0 1.579  101 exp(6.509  102  Vm)
m ¼(a0  ai  bb)/(aa  bi)
hERG and the chimera transition rates (ms1)
ai 4.0  102 exp(-3.0  102  Vm)
bi 2.3  101 exp(1.6  102  Vm)
Vm, membrane potential (mV).Biophysical Journal 97(5) 1323–1334
1330 Choveau et al.FIGURE 5 Effect of BeKm-1 on hERG and the chimera. Representative currents of (A) hERG and the (B) chimera in baseline conditions and after a 3-min
exposure to 25 nM BeKm-1 elicited by an ascending voltage ramp (10 mV/s; every 15 s). (C) Mean fractional block (1  (current in the presence of 25 nM
BeKm-1/baseline current)) measured at various potentials during the depolarizing ramp in cells expressing hERG (n ¼ 6) or chimeric (n ¼ 7) channels.
*p < 0.05; **p < 0.01; ***p < 0.001. (Solid triangles) Mean steady-state fractional block measured at the end of a 5-s step to 30 mV (n ¼ 6), 0 mV
(n ¼ 7), or þ40 mV (n ¼ 7) in cells expressing hERG.inactivation (Fig. 5 B). Then, ramp stimulation was stopped,
membrane potential was clamped at 80 mV, and 25 nM
BeKm-1 was applied. After 3 min of exposure to the toxin,
the stimulation was applied again and the first recorded
current ramp was used to evaluate BeKm-1 effects (15). As
summarized in Fig. 5 C, inhibition of hERG by BeKm-1
was higher at negative voltages and declined at more positive
voltages. ANOVA analysis of BeKm-1 inhibition at the
different voltages showed a significant voltage-dependence
of the block (n ¼ 6, one-way repeated measures ANOVA;
p < 0.001). To check whether the ramp was slow enough
to look at the steady-state block, 5-s steps at 30, 0, or
þ40 mV were also applied from a holding potential of
80 mV in the same conditions (28). The steady-state frac-
tional block measured with the step protocol was similar
(Fig. 5 C) showing that the ramp was slow enough to get
the steady-state block. As opposed to hERG, the chimera
was weakly inhibited by BeKm-1 and this inhibition was
voltage-independent (NS). Fractional block of the chimera
significantly differed fromWT at potentials between30mV
andþ20mV (two-way ANOVA, with a Tukey test) and were
similar at higher potentials, when both channels are inacti-
vated (Fig. 5 C). The persistence of a fractional block
(~20%) suggests that the toxin can bind not only to closed
Biophysical Journal 97(5) 1323–1334but also to open and inactivated channels (although with
a lower affinity). An alternative hypothesis would be the
persistence of a closed state in the chimeric channel, allowing
toxin binding. A direct measurement of channel open proba-
bility by using single channel methods will be necessary to
discriminate one of the two hypotheses.
Sensitivity to E-4031 suggests an intact pore
in the chimera
We described a hERG mutant (D540K) that was activated at
hyperpolarizing potentials (see Introduction). This mutant
may not be relevant to study the coupling between activation
and inactivation because the mutation is close to the pore
domain, in which conformational changes are associated
with both activation and inactivation (9). This is confirmed
by the use of methanesulfonanilide blockers such as
MK-499 and E-4031. Because these blockers are known to
target the hERG pore (29,30), the altered sensitivity to
MK-499 confirms the effect of the mutation on the pore
domain. We tested the effect of E-4031 to determine if the
chimera pore was affected similarly to the D540K mutant. In
these experiments, hERG and the chimera currents were
elicited by a 500-ms depolarizing pulse to þ10 mV from
Properties of a Two-State hERG Mutant 1331FIGURE 6 Effect of ketoconazole (keto) on hERG and the chimera. Representative currents of (A) hERG and (B) chimera in baseline conditions and after
3-min exposure to 5 mM keto elicited by an ascending voltage ramp (10 mV/s; every 15 s). (C) Mean fractional block (1  (current in the presence of 5 mM
keto/baseline current)) measured at various potentials during the depolarizing ramp in cells expressing hERG (n¼ 8) or chimeric (n¼ 6) channels. **p< 0.01;
***p < 0.001.a holding potential of 80 mV and the tail current was re-
corded at60mV. Depolarizing steps were applied every 3 s.
The dose-response curve for E-4031 inhibition of the tail
current showed an IC50 of 465 29 nM and a Hill coefficient
of 0.72 5 0.17 for hERG (n ¼ 6, data not shown). For the
chimera, the IC50 was 36 5 18 nM and the Hill coefficient
was 0.895 0.24 (n ¼ 7). There was no difference between
hERG and the chimera sensitivity to E-4031 (Student’s
t-test,NS). This result confirms that only deactivation is altered
in the chimera and that the inactivation and pore are intact.
The chimera indicates that ketoconazole binds
preferentially to the open and inactivated states
This preliminary validation of the chimera model to study
hERG pharmacology allowed us to evaluate the mechanism
of hERG inhibition by ketoconazole. Several studies suggest
that ketoconazole inhibits hERG preferentially in the closed
state (14,16). However, another study has shown that this
drug binds preferentially to the open state (15). To determine
the mechanism of action of ketoconazole, we tested its effects
on hERGand the chimera. The same protocol aswithBeKm-1
was applied. The ramp was slow enough to obtain the steady-
state block, because ketoconazole block is much faster than
BeKm-1 block (15). If ketoconazole binds preferentially the
closed state, we should observe a higher hERG inhibition atnegative voltages, which declines at more positive voltages
and a weak inhibition of the chimera in the presence of the
drug. Contrarily to this hypothesis, but in agreement with
Ridley and coworkers, hERG inhibition increased progres-
sively with the potential, reaching a maximum at 0 mV
(one-way repeated measures ANOVA; p < 0.001) (Fig. 6,
A and C). The difficulty with hERG is that small current
amplitude prevents an accurate measurement of the fractional
block, particularly at -40 or -30 mV in some cells due to low
activation. Because of its full activation, the chimera allowed
a more accurate estimation of this fractional block at negative
voltages. The chimera was strongly inhibited whatever
the voltage was (Fig. 6, B and C). Fractional block of the
chimera significantly differed from hERG at potentials
between 30 mV and 10 mV (two-way ANOVA, with a
Tukey test). The much lower ketoconazole block of hERG
at negative potentials indicates that ketoconazole binds less
to hERG closed state than open and inactivated ones.
DISCUSSION
Transfer of voltage independence from rolf
to hERG
In this study, we described the biophysical properties of
a rolf-hERG S3-S4 chimera. Our results show that only theBiophysical Journal 97(5) 1323–1334
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inactivation is conserved because the chimera has the same
inactivation and recovery from inactivation properties as
the hERG channel. These results show that the modification
of the activation process does not modify the inactivation.
It seems that activation is not necessary to trigger inactiva-
tion. Otherwise, we would observe a change of the inactiva-
tion biophysical parameters. To evaluate the effects of the
impaired activation on the inactivation process, we opti-
mized the Markov model developed by Clancy and Rudy
for hERG kinetics (19). In this model, we convincingly
simulated the chimera properties by conserving only the
transitions between the open and inactivated states of
hERG. We found that the chimera currents are well fitted by
this two-state model, reinforcing the hypothesis of a two-
state channel. These models are consistent with a weak, if
any, relationship between the conformational changes
associated with inactivation and those associated with
activation because the alteration of the latter in the chimera
does not seem to alter the former. However, the models do
not exclude that activation and inactivation are indirectly
coupled by being both controlled by the movement of the
voltage sensor because the hERG model suggests a move-
ment of the voltage sensor (early transitions) followed by
movements of the activation and inactivation gates (late
transitions). Several studies are consistent with this idea.
Loots and Isacoff (31) proposed that, in Shaker, activation
produces an interaction between S4 and the pore domain.
This interaction disrupts the coupling between S5 and S6
domains and leads to inactivation. Regarding hERG, two
studies (7,32) suggest that the coupling between the activa-
tion and inactivation is mediated by the S4 domain. To probe
the voltage-sensor movements, Smith and Yellen (32) used
a fluorescence technique to examine the conformational
changes of hERG S4. Fluorescent probes attached to three
different residues on S3-S4 (E518C, E519C, and L520C)
reported both fast and slow voltage-dependent changes in
fluorescence. The authors suggested that the fast component
corresponds to inactivation, and the slow component to acti-
vation. Consequently, it seems that voltage-dependent inac-
tivation is linked to the voltage sensor. However, Hill et al.
(33) showed recently that neutralization of the first three
charges in the hERG S4 domain (K525Q, R528Q, R531Q)
shifts the voltage-dependent activation of 87 mV toward
negative potentials but does not modify the voltage-depen-
dent inactivation. These results suggest that unlike activa-
tion, hERG inactivation is independent of the S4 movement
and reinforce the hypothesis that activation and inactivation
are two distinct mechanisms. The same group also carried
out an alanine scan of S5 of hERG. Mapping of the func-
tional effect of the mutations on a hERG homology domain
clearly shows distinct areas. The residues pointing toward S6
are associated with an altered inactivation process, whereas
many residues pointing away and most of the S4-S5 linker
are associated with an altered activation process (34). This
Biophysical Journal 97(5) 1323–1334is also consistent with uncoupled activation and inactivation
processes.
Besides an intact inactivation mechanism, the chimera
conserves an intact pore as suggested by the comparison of
hERG and the chimera blockade by drugs. We tested the
sensitivity of the chimera to E-4031 (29) and found that
the chimera exhibits the same sensitivity as hERG. The
hERG D540K mutant is also activated at hyperpolarized
potentials but conserves the ability to activate and inactivate
in response to membrane depolarization (9). However, unlike
the chimera, thismutant hasmodified inactivation and a lower
sensitivity to MK-499, another methanesulfonanilide (11).
The differences between the chimera and the D540K mutant
may find their origin in the impairment of distinct mecha-
nisms. In hERG channels, the interaction between the
S4-S5 linker (containing D540) and the C-terminal end of
the S6 domain allows the coupled movements between the
voltage sensor and the activation gate (10). In the D540K
mutant, the altered interaction between the voltage sensor
and the activation gate may promote channel reopening at
hyperpolarized potentials (35). In the chimera, themechanism
involved in the voltage independence of activation may arise
from constrained movements of the voltage sensor, upstream
of S4-pore coupling. In other words, the S3-S4 substitution
would impair the S4 movement but not the coupling between
the voltage sensor and the pore. To confirm this hypothesis,
gating current measurements will be helpful to determine
whether or not the rolf S3-S4 linker limits the movements
of the S4 segment in the chimera.
The role of the S3-S4 linker has been studied widely in the
Shaker channel (36–38). The large deletion of amino acids
333–357 in the S3-S4 linker has only minor effects on the
voltage dependence of activation (37). However, amino
acids 330–360 deletion leads to a þ45-mV shift (36). These
results suggest that it is probably not the length of the linker
that critically constrains the S4 segment displacement but
rather the nature of its amino-acid sequence. We replaced
10 amino acids of hERG S3-S4 linker by nine amino acids
of rolf and observed a major effect on activation. Interest-
ingly, this replacement includes amino acid E246 in rolf:
substitution of this amino acid to the equivalent position in
eag (A345E) has been shown to stabilize the activation
gate of the eag (13). To further explore the role of S3-S4
loop in the hERG voltage sensor, a scanning mutagenesis
of the S3-S4 loop in the hERG-rolf chimera will allow iden-
tifying the specific residues involved in the alteration of the
chimera activation.
Use of the chimera as a pharmacological model
Our results show that the chimera has a lower sensitivity to
BeKm-1, a blocker that binds preferentially to the channel
closed-state. This observation reinforces the idea that the
chimera exists mostly in two conformations: open or inacti-
vated. We have used this chimera property to study the
Properties of a Two-State hERG Mutant 1333mechanism of ketoconazole action. Two mechanisms have
been suggested: a block in the closed state (14,16) or a block
in the open or inactivated state (15). We have shown that
ketoconazole binds preferentially to the open and inactivated
states. This conclusion relies on the assumption that the drug
effect on the chimera can be extrapolated to hERG. Two
arguments suggest that the binding of ketoconazole to
hERG is not modified by the S3-S4 substitution. First, the
binding site of ketoconazole does not implicate the S3-S4
linker because it is located in the intracellular part of S6
(15). The second argument is that the effects of ketoconazole
on hERG and the chimera are similar at potentials (þ20 to
þ40 mV) at which both channels reside in the same states
(open and inactivated).
Focusing on the chimera, fractional block decreased
significantly between 40 mV and potentials þ20, þ30,
and þ40 mV (one-way repeated measures ANOVA, with a
Tukey test), reminiscent of the voltage-dependent block
observed with miconazole (39). This may suggest that keto-
conazole binds the open channels with a higher affinity than
the inactivated channels. However, the voltage dependence
of the chimera block does not parallel that of inactivation:
the potential for half fractional block is ~0 mV, which is
much closer to the half-activation potential (4.9 mV)
than the half-inactivation potential (from 50 to 70 mV
depending on the protocol used). This lead to the hypothesis
that some structural rearrangements linked to the normal
activation process are conserved in the chimera despite the
absence of activation gating, and that these rearrangements
are responsible for the voltage-dependent interaction of keto-
conazole with the chimeric channel.
The mechanism of hERG block by several drugs associ-
ated with the acquired long QT syndrome remains unclear.
Indeed, moxifloxacin (40), fluvoxamine (41), and, recently,
doxepin (42) have been reported to inhibit hERG with
a mixed state-dependence of inhibition (with components
of both closed- and open-channel block, including a very
rapid open-channel block). The results presented in this
study suggest that hERG-rolf chimera is a valuable pharma-
cological model to characterize the state-dependent block
and more generally, to identify the mechanism of action of
hERG blockers.
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